MX2021008941A - Moduladores gpr35. - Google Patents

Moduladores gpr35.

Info

Publication number
MX2021008941A
MX2021008941A MX2021008941A MX2021008941A MX2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A MX 2021008941 A MX2021008941 A MX 2021008941A
Authority
MX
Mexico
Prior art keywords
gpr35
modulators
gpr35 modulators
compounds
disorders
Prior art date
Application number
MX2021008941A
Other languages
English (en)
Spanish (es)
Inventor
Robert Higuchi
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of MX2021008941A publication Critical patent/MX2021008941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021008941A 2019-01-24 2020-01-23 Moduladores gpr35. MX2021008941A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US201962928223P 2019-10-30 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (1)

Publication Number Publication Date
MX2021008941A true MX2021008941A (es) 2021-10-13

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008941A MX2021008941A (es) 2019-01-24 2020-01-23 Moduladores gpr35.

Country Status (13)

Country Link
US (2) US11053251B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914256B1 (cg-RX-API-DMAC7.html)
JP (1) JP7588077B2 (cg-RX-API-DMAC7.html)
KR (1) KR102863894B1 (cg-RX-API-DMAC7.html)
CN (1) CN113631168B (cg-RX-API-DMAC7.html)
AU (1) AU2020210930B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014566A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127786A1 (cg-RX-API-DMAC7.html)
IL (1) IL285074B2 (cg-RX-API-DMAC7.html)
MA (1) MA54825A (cg-RX-API-DMAC7.html)
MX (1) MX2021008941A (cg-RX-API-DMAC7.html)
TW (1) TWI845600B (cg-RX-API-DMAC7.html)
WO (1) WO2020154492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
AR123034A1 (es) * 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) * 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
WO2005085867A2 (en) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
CA3168304A1 (en) 2014-06-29 2016-01-07 Profile Products L.L.C. Bark and wood fiber growing medium
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CA3128942A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
JP2022519819A (ja) 2019-02-08 2022-03-25 シーダーズ―シナイ メディカル センター Il18r1を標的とする炎症性疾患を処置するための方法、システム、およびキット
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
AR123034A1 (es) 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35
IL302791A (en) 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4263585A4 (en) 2020-12-21 2024-11-27 Cedars-Sinai Medical Center THERAPEUTIC COMPOSITIONS OF TL1A AND METHODS OF TREATMENT USING THEM

Also Published As

Publication number Publication date
EP3914256B1 (en) 2024-05-29
US20200239476A1 (en) 2020-07-30
US11773101B2 (en) 2023-10-03
IL285074A (en) 2021-09-30
CN113631168A (zh) 2021-11-09
EP3914256A1 (en) 2021-12-01
US20210380590A1 (en) 2021-12-09
US11053251B2 (en) 2021-07-06
TW202043234A (zh) 2020-12-01
TWI845600B (zh) 2024-06-21
BR112021014566A2 (pt) 2022-01-04
IL285074B1 (en) 2024-08-01
AU2020210930A1 (en) 2021-09-09
CA3127786A1 (en) 2020-07-30
WO2020154492A1 (en) 2020-07-30
JP7588077B2 (ja) 2024-11-21
CN113631168B (zh) 2024-11-19
EP3914256A4 (en) 2022-09-28
JP2022518523A (ja) 2022-03-15
MA54825A (fr) 2021-12-01
KR102863894B1 (ko) 2025-09-23
AU2020210930B2 (en) 2025-08-14
IL285074B2 (en) 2024-12-01
KR20210119485A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
PH12020550523A1 (en) Modulators of the integrated stress pathway
ECSP21086429A (es) Moduladores de la vía integrada del estrés
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
ECSP20027553A (es) Moduladores de la vía de estrés integrada
MX2020004557A (es) Moduladores de la vía de estrés integrada.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
MX2020004558A (es) Moduladores de la vía de estrés integrada.
CO2024013744A2 (es) Moduladores de nlrp3
EA201992083A1 (ru) Модуляторы соматостатина и их применения
MX2020004519A (es) Moduladores de la vía de estrés integrada.
MX2020004556A (es) Moduladores de la vía de estrés integrada.
AU2017261336A1 (en) Modulators of the integrated stress pathway
MX390120B (es) Moduladores de la somatostatina y usos de los mismos.
AU2017260374A1 (en) Modulators of the integrated stress pathway
MX2022000712A (es) Moduladores de nlrp3.
CO2022014499A2 (es) Moduladores de nlrp3
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
CL2019002583A1 (es) Inhibidores duales de magl y faah.
BR112021014566A2 (pt) Moduladores de gpr35
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX379440B (es) Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7